Comprehensive Stock Comparison
Compare BioMarin Pharmaceutical Inc. (BMRN) vs PTC Therapeutics, Inc. (PTCT) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | PTCT | 114.5% revenue growth vs BMRN's 12.9% |
| Value | PTCT | Lower P/E (8.8x vs 15.4x) |
| Quality / Margins | PTCT | 42.3% net margin vs BMRN's 10.8% |
| Stability / Safety | BMRN | Beta 0.74 vs PTCT's 0.91 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | PTCT | +23.4% vs BMRN's -13.3% |
| Efficiency (ROA) | PTCT | 28.4% ROA vs BMRN's 4.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing therapies for rare genetic diseases. It generates revenue primarily from sales of its orphan drug portfolio — including Voxzogo, Vimizim, and Palynziq — with additional income from licensing and royalties. The company's moat lies in its deep expertise in rare disease biology and its established commercial infrastructure for ultra-orphan drugs, which creates high barriers to entry.
PTC Therapeutics is a biopharmaceutical company that develops and commercializes treatments for rare genetic disorders. It generates revenue primarily from sales of its approved therapies for Duchenne muscular dystrophy and spinal muscular atrophy — with additional income from collaborations and licensing agreements. The company's competitive advantage lies in its proprietary RNA-targeting and splicing technologies that enable it to address previously untreatable genetic mutations.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
PTCT leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). BMRN leads in 1 (Risk & Volatility). 1 tied.
Financial Metrics (TTM)
BMRN is the larger business by revenue, generating $3.2B annually — 1.8x PTCT's $1.8B. PTCT is the more profitable business, keeping 42.3% of every revenue dollar as net income compared to BMRN's 10.8%. On growth, BMRN holds the edge at +17.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BMRNBioMarin Pharmace… | PTCTPTC Therapeutics,… |
|---|---|---|
| RevenueTrailing 12 months | $3.2B | $1.8B |
| EBITDAEarnings before interest/tax | $613M | $809M |
| Net IncomeAfter-tax profit | $349M | $752M |
| Free Cash FlowCash after capex | $725M | $699M |
| Gross MarginGross profit ÷ Revenue | +77.1% | +91.2% |
| Operating MarginEBIT ÷ Revenue | +16.6% | +43.6% |
| Net MarginNet income ÷ Revenue | +10.8% | +42.3% |
| FCF MarginFCF ÷ Revenue | +22.5% | +39.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +17.0% | +7.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -134.4% | +114.4% |
Valuation Metrics
At 8.8x trailing earnings, PTCT trades at a 74% valuation discount to BMRN's 34.3x P/E. On an enterprise value basis, PTCT's 5.6x EV/EBITDA is more attractive than BMRN's 18.2x.
| Metric | BMRNBioMarin Pharmace… | PTCTPTC Therapeutics,… |
|---|---|---|
| Market CapShares × price | $11.9B | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $11.1B | $4.9B |
| Trailing P/EPrice ÷ TTM EPS | 34.29x | 8.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 15.45x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 18.18x | 5.61x |
| Price / SalesMarket cap ÷ Revenue | 3.68x | 3.15x |
| Price / BookPrice ÷ Book value/share | 2.00x | — |
| Price / FCFMarket cap ÷ FCF | 16.36x | — |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), BMRN scores 5/9 vs PTCT's 4/9, reflecting solid financial health.
| Metric | BMRNBioMarin Pharmace… | PTCTPTC Therapeutics,… |
|---|---|---|
| ROE (TTM)Return on equity | +5.7% | — |
| ROA (TTM)Return on assets | +4.6% | +28.4% |
| ROICReturn on invested capital | +7.4% | — |
| ROCEReturn on capital employed | +7.8% | +56.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.10x | — |
| Net DebtTotal debt minus cash | -$715M | -$586M |
| Cash & Equiv.Liquid assets | $1.3B | $985M |
| Total DebtShort + long-term debt | $597M | $399M |
| Interest CoverageEBIT ÷ Interest expense | 48.95x | 6.37x |
Total Returns (with DRIP)
A $10,000 investment in PTCT five years ago would be worth $11,725 today (with dividends reinvested), compared to $7,797 for BMRN. Over the past 12 months, PTCT leads with a +23.4% total return vs BMRN's -13.3%. The 3-year compound annual growth rate (CAGR) favors PTCT at 16.0% vs BMRN's -14.7% — a key indicator of consistent wealth creation.
| Metric | BMRNBioMarin Pharmace… | PTCTPTC Therapeutics,… |
|---|---|---|
| YTD ReturnYear-to-date | +3.8% | -11.1% |
| 1-Year ReturnPast 12 months | -13.3% | +23.4% |
| 3-Year ReturnCumulative with dividends | -38.0% | +56.1% |
| 5-Year ReturnCumulative with dividends | -22.0% | +17.2% |
| 10-Year ReturnCumulative with dividends | -24.6% | +754.5% |
| CAGR (3Y)Annualised 3-year return | -14.7% | +16.0% |
Risk & Volatility
BMRN is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than PTCT's 0.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BMRN currently trades 84.0% from its 52-week high vs PTCT's 77.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BMRNBioMarin Pharmace… | PTCTPTC Therapeutics,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 0.91x |
| 52-Week HighHighest price in past year | $73.51 | $87.50 |
| 52-Week LowLowest price in past year | $50.76 | $35.95 |
| % of 52W HighCurrent price vs 52-week peak | +84.0% | +77.9% |
| RSI (14)Momentum oscillator 0–100 | 56.6 | 35.0 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 994K |
Analyst Outlook
Wall Street rates BMRN as "Buy" and PTCT as "Buy". Consensus price targets imply 32.8% upside for BMRN (target: $82) vs 23.9% for PTCT (target: $85).
| Metric | BMRNBioMarin Pharmace… | PTCTPTC Therapeutics,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $82.00 | $84.50 |
| # AnalystsCovering analysts | 40 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | 100 | 61.39 | -38.6% |
| PTC Therapeutics, I… (PTCT) | 100 | 136.32 | +36.3% |
PTC Therapeutics, I… (PTCT) returned +17% over 5 years vs BioMarin Pharmaceut… (BMRN)'s -22%. A $10,000 investment in PTCT 5 years ago would be worth $11,725 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | $1.1B | $0.00 | -100.0% |
| PTC Therapeutics, I… (PTCT) | $83M | $1.7B | +1992.6% |
BioMarin Pharmaceutical Inc.'s revenue grew from $1.1B (2016) to $0M (2025) — a -100.0% CAGR. PTC Therapeutics, Inc.'s revenue grew from $83M (2016) to $1.7B (2025) — a 40.2% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | -56.4% | 15.0% | +126.5% |
| PTC Therapeutics, I… (PTCT) | -171.8% | 39.4% | +123.0% |
PTC Therapeutics, Inc.'s net margin went from -172% (2016) to 39% (2025).
Chart 4P/E Ratio History — 5 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | 19.4 | 424.5 | +2088.1% |
BioMarin Pharmaceutical Inc. has traded in a 19x–425x P/E range over 5 years; current trailing P/E is ~34x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | -3.79 | 0.14 | +103.7% |
| PTC Therapeutics, I… (PTCT) | -4.17 | 7.78 | +286.6% |
BioMarin Pharmaceutical Inc.'s EPS grew from $-3.79 (2016) to $0.14 (2025). PTC Therapeutics, Inc.'s EPS grew from $-4.17 (2016) to $7.78 (2025).
Chart 6Free Cash Flow — 5 Years
BioMarin Pharmaceutical Inc. generated $725M FCF in 2025 (+291% vs 2021). PTC Therapeutics, Inc. generated $0M FCF in 2025 (+100% vs 2021).
BMRN vs PTCT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is BMRN or PTCT a better buy right now?
PTC Therapeutics, Inc. (PTCT) offers the better valuation at 8.8x trailing P/E, making it the more compelling value choice. Analysts rate BioMarin Pharmaceutical Inc. (BMRN) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BMRN or PTCT?
On trailing P/E, PTC Therapeutics, Inc. (PTCT) is the cheapest at 8.8x versus BioMarin Pharmaceutical Inc. at 34.3x.
03Which is the better long-term investment — BMRN or PTCT?
Over the past 5 years, PTC Therapeutics, Inc. (PTCT) delivered a total return of +17.2%, compared to -22.0% for BioMarin Pharmaceutical Inc. (BMRN). A $10,000 investment in PTCT five years ago would be worth approximately $12K today (assuming dividends reinvested). Over 10 years, the gap is even starker: PTCT returned +754.5% versus BMRN's -24.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BMRN or PTCT?
By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc. (BMRN) is the lower-risk stock at 0.74β versus PTC Therapeutics, Inc.'s 0.91β — meaning PTCT is approximately 22% more volatile than BMRN relative to the S&P 500.
05Which has better profit margins — BMRN or PTCT?
PTC Therapeutics, Inc. (PTCT) is the more profitable company, earning 39.4% net margin versus 10.8% for BioMarin Pharmaceutical Inc. — meaning it keeps 39.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 50.1% versus 16.6% for BMRN. At the gross margin level — before operating expenses — PTCT leads at 91.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is BMRN or PTCT more undervalued right now?
Analyst consensus price targets imply the most upside for BMRN: 32.8% to $82.00.
07Which pays a better dividend — BMRN or PTCT?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is BMRN or PTCT better for a retirement portfolio?
For long-horizon retirement investors, PTC Therapeutics, Inc. (PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.91), +754.5% 10Y return). Both have compounded well over 10 years (PTCT: +754.5%, BMRN: -24.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BMRN and PTCT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: BMRN is a mid-cap quality compounder stock; PTCT is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.